HomeEducationEducation CoursesPsychiatric Disorders in Women: Diagnostic and Treatment Considerations Across the Female Lifespan (March 2021)

Psychiatric Disorders in Women: Diagnostic and Treatment Considerations Across the Female Lifespan (March 2021)

Event Date(s): Mar 15, 2021 - 01:00am to May 3, 2021 - 11:59pm

This course will focus on the diagnosis and treatment of psychiatric disorders in women across the reproductive lifespan.  Specialized knowledge is necessary to tailor treatments to reproductive events such as pregnancy and pregnancy planning, the postpartum, breastfeeding, the menopausal transition, and menstrual cycle related mood dysregulation.  Exposure to psychotropic medications and the consequence of untreated psychiatric disorders must be considered when treating pregnant women, those who may become pregnant during treatment, and those who are breastfeeding.  Up to date and comprehensive knowledge is required to help patients make collaborative and individualized treatment decisions. Focused material will also be presented regarding the treatment of premenstrual dysphoric disorder and premenstrual mood exacerbation, as well as treatment considerations for the menopausal transition. Learning in this course will be facilitated by didactic materials delivered by the faculty from the MGH Center for Women’s Mental Health.  Faculty will also facilitate question and answer and case-based discussion sessions for course participants.  Readings to accompany course materials will also be provided.

Available Credits: 13.75 AMA PRA Category 1 Credit™ 13.75 Nursing Contact Hours 13.75 Social Workers 13.75 Participation 13.75 Psychologists CE Credit Register For This Course

Course Details

This course will focus on the diagnosis and treatment of psychiatric disorders in women across the reproductive lifespan.  Specialized knowledge is necessary to tailor treatments to reproductive events such as pregnancy and pregnancy planning, the postpartum, breastfeeding, the menopausal transition, and menstrual cycle related mood dysregulation.  Exposure to psychotropic medications and the consequence of untreated psychiatric disorders must be considered when treating pregnant women, those who may become pregnant during treatment, and those who are breastfeeding.  Up to date and comprehensive knowledge is required to help patients make collaborative and individualized treatment decisions. Focused material will also be presented regarding the treatment of premenstrual dysphoric disorder and premenstrual mood exacerbation, as well as treatment considerations for the menopausal transition. Learning in this course will be facilitated by didactic materials delivered by the faculty from the MGH Center for Women’s Mental Health.  Faculty will also facilitate question and answer and case-based discussion sessions for course participants.  Readings to accompany course materials will also be provided.

Pricing

Registration Deadline: March 29, 2021

Physicians and Doctoral-level Professionals: $445.00
Other Professionals: $345.00

Restriction on Use of Materials

This site is operated and maintained by The Massachusetts General Hospital Psychiatry Academy. No material or information from this site may be copied, reproduced, republished, uploaded, posted, transmitted or distributed unless approved in writing by The Psychiatry Academy. Questions concerning the proper use of materials and information in this site should be directed to: mghcme@mgh.harvard.edu. No rights or licenses of any kind of The Psychiatry Academy’s intellectual property are transferred to, granted to, provided to or received by you as a result of using this web site.

Cancellation Policy

Refunds will be issued for cancellation requests made during the first week of the course, but an administrative fee of $25.00 will be deducted from your refund.  Cancellation requests made during the second week will receive a credit toward a future offering of the same course.  No refunds or credits will be granted after March 29, 2021.

Q&A with Faculty
 

Welcome to  Psychiatric Disorders in Women: Diagnostic and Treatment Considerations Across the Female Lifespan.

Each week, the faculty will be answering questions relating to the webinars and readings.

Please prepare your questions in advance of the call and submit them to  womensmentalhealth@mgh.harvard.edu. If time permits, you may be able to ask questions that have not been pre-submitted, but to guarantee your query is addressed  please send in your questions by close of business the day prior. Please see the weekly call schedule below:

Week Start Date

Date of Q&A

Time of Q&A

Q&A Moderator

Week 1: 3/15/2021 
Major Depressive Disorder in Pregnancy and the Postpartum

 3/16/2021

1:00 PM EST

Lee Cohen, MD

Week 2: 3/22/2021
Bipolar Disorder: Considerations Across the Reproductive Lifespan

 3/23/2021

1:00 PM EST

Marlene Freeman, MD

Week 3: 3/29/2021
Premenstrual Dysphoric Disorder (PMDD)

 3/30/2021

1:00 PM EST

Laura Fagioli-Petrillo, MD

Week 4: 4/5/2021
The Menopausal Transition and Depression

 4/6/2021

1:00 PM EST

Ruta Nonacs, MD, PhD

Week 5: 4/12/2021
Substance Use Disorders and Posttraumatic Stress Disorder in Women of Reproductive Age

 4/13/2021

1:00 PM EST

Edwin Raffi, MD, MPH

Week 6: 4/19/2021
ADHD in Women

 4/20/2021

1:00 PM EST

Allison Baker, MD

Course Summary

Available Credits:13.75 AMA PRA Category 1 Credit™ 13.75 Nursing Contact Hours 13.75 Social Workers 13.75 Participation 13.75 Psychologists CE Credit
Course Topic:Women's Mental Health
Course Format:Online CBT Course
Target Audience:

This program is intended for:

  • Psychiatrists
  • Primary care physicians
  • Nurse practitioners
  • Social workers
  • Psychologists
  • OB-GYN'S
  • Midwives
Event Starts: Mar 15, 2021 - 01:00am
Event Ends: May 3, 2021 - 11:59pm
Cost: $445.00

Learning Objectives

By the end of this program, participants will be able to:

Week 1: Major Depressive Disorder in Pregnancy and the Postpartum

•     Describe critical research findings in reproductive psychiatry that inform clinical care
•     Recognize the current knowledge gaps in reproductive neuroscience with respect to perinatal depression
•     Receive an update regarding reproductive safety of psychiatric medication during pregnancy and management strategies for screening and treatment of postpartum depression

Week 2: Bipolar Disorder: Considerations Across the Reproductive Lifespan

•     Frame the treatment of reproductive aged women with bipolar disorder from the standpoint of reproductive safety
•     Discuss the relative safety of pharmacologic treatments used in bipolar disorder in consideration of pregnancy
•     Consider multiple and patient-centered variables in treatment selection for pregnant and reproductive-aged women with bipolar disorder

Week 3: Premenstrual Dysphoric Disorder (PMDD)

•     Identify evidenced based treatments for PMDD, including psychotropic, hormonal and lifestyle modification options
•     Describe the pathophysiology of PMDD
•     Recognize the diagnostic criteria for PMDD outlined in DSM-5

Week 4: The Menopausal Transition and Depression

•     Distinguish normal physical, hormonal and emotional changes at menopause from pathophysiologic conditions occurring during the menopausal transition
•     Discuss the pathophysiology of and the role of hormonal changes in psychiatric illness emerging during the menopausal transition
•     Identify appropriate treatment options for mood and anxiety disorders in midlife women 

Week 5: Substance Use Disorders and Posttraumatic Stress Disorder in Women of Reproductive Age

•     Identify the etiology of co-occurring PTSD and SUD in women
•     Discuss screening for and diagnosis of co-occurring PTSD and SUD in women
•     Describe best treatment modalities for co-occurring PTSD and SUD in women

Week 6: ADHD in Women

•     Discuss general risks of stimulant use during pregnancy and lactation with their patients with ADHD
•     Create a tailored risk/risk analysis of stimulant use vs. risk of stopping treatment for their patient with ADHD
•     Describe the non-pharmacologic treatment options available to their patients with ADHD

We have a dedicated staff member who is available by phone 5 days per week between 8 am and 5 pm by calling 866-644-7792 or email at mghcme@mgh.harvard.edu. All inquiries will be dealt with in a timely  (within one business day) and professional manner. Requests for credits or refunds will be reviewed by the Director of the Division of Professional and Public Education, Massachusetts General Hospital. Please refer to our cancellation policy for additional information.”